



## Personalized Management in Psoriasis and Atopic Dermatitis

Guest Editors:

**Dr. Mario Valenti**

1. Dermatology Unit, IRCCS  
Humanitas Research Hospital,  
Milan, Italy  
2. Department of Biomedical  
Sciences, Humanitas University,  
Milan, Italy

**Prof. Dr. Antonio Costanzo**

1. Dermatology Unit, Department  
of Biomedical Sciences,  
Humanitas University, 20072  
Pieve Emanuele, Italy  
2. Humanitas Clinical and  
Research Center, Scientific  
Institute for Research,  
Hospitalization and Healthcare,  
20089 Rozzano, Italy

Deadline for manuscript  
submissions:

**20 March 2025**

### Message from the Guest Editors

The development of a multitude of biological drugs and small molecules (e.g., JAK inhibitors) has led to a paradigm shift in the treatment of inflammatory skin diseases. These drugs are changing the lives of millions of dermatological patients around the world, and they are also helping clinicians to better understand the pathophysiology of several immune-mediated cutaneous diseases, including psoriasis, atopic dermatitis, chronic urticaria, and hidradenitis suppurativa; however, data are still limited on the place in therapy of different drugs in each subpopulation of patients, according to comorbidities, disease severity, and previous exposure to other systemic drugs. Furthermore, the search for biomarkers that might help with classification and therapy selection is still ongoing. In this Special Issue, we will focus on new drugs for the treatment of psoriasis and atopic dermatitis, with a particular interest in real-world experiences, with the aim to explore possible tailor-made treatments for each patient.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)